A simple inclusion criteria combination increases the rate of cartilage loss in patients with knee osteoarthritis. Issue 3 (September 2021)

• Record Type: Journal Article
• Authors: Imbert, Olivier; Chimits, Damien; Guedj, Mickaël; Lorieau, Freddy; Bernard, Katy; Lalande, Agnès; Wirth, Wolfgang; Eckstein, Felix; Pueyo, Maria
• Is Part Of: Osteoarthritis and cartilage open. Volume 3:Issue 3(2021)
• Publication Date: 2021-09
• Subjects: Osteoarthritis -- Knee -- Magnetic resonance imaging -- Qualitative research; Osteoarthritis -- Periodicals; Cartilage -- Periodicals; 616.7223005
• DOI: 10.1016/j.ocarto.2021.100188
• Languages: English
• ISSNs: 2665-9131

Abstract

Abstract: Objectives: Selection of patients with KL radiographic grade 2 and 3 is widely used in clinical trials, but this approach could have some limitations. The purpose of this study performed on OsteoArthritis Initiative (OAI) data is to assess whether adding OARSI-JSN to KL grading could select a population with increased rate of cartilage loss. Indeed, KL is not compartment-specific and not uniformly graded amongst expert readers. OARSI-JSN is another established, compartment-specific grading scale that specifically captures the joint space narrowing from radiographs. Design: 1019 knee radiographs data from the progression cohort of the OAI public database were used. Cartilage loss measured with magnetic resonance imaging was evaluated using change over 1 year from baseline in cartilage thickness in the central Medial Tibio-Femoral Compartment (cMTFC) in the KL2-3 and KL2-3 +JSN1-2 populations. Results: The mean cMTFC cartilage loss over one year was −0.135 ​± ​0.29 ​mm (median ​= ​−0.095 ​mm) in the KL2-3 population and −0.176 ​± ​0.29 ​mm (median ​= ​−0.140 ​mm) in the KL2-3 +JSN1-2 population. Conclusions: OARSI-JSN appears to be an effective inclusion criterion to be considered in combination with the KL grade in future clinical trials testing the structural efficacy of DMOADs in a time window of 1-year as it contributes to identify knees in whom the disease progresses rapidly.